Roxanne Austin Net Worth

The estimated Net Worth of Roxanne S Austin is at least $72.5 Million dollars as of 28 June 2024. Ms. Austin owns over 5,000 units of Abbvie Inc stock worth over $3,560,413 and over the last 21 years she sold ABBV stock worth over $68,575,936. In addition, she makes $333,427 as Independent Director at Abbvie Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Austin ABBV stock SEC Form 4 insiders trading

Roxanne has made over 44 trades of the Abbvie Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she sold 5,000 units of ABBV stock worth $1,955,050 on 28 June 2024.

The largest trade she's ever made was selling 90,000 units of Abbvie Inc stock on 1 October 2020 worth over $12,880,800. On average, Roxanne trades about 4,488 units every 31 days since 2003. As of 28 June 2024 she still owns at least 18,297 units of Abbvie Inc stock.

You can see the complete history of Ms. Austin stock trades at the bottom of the page.

Roxanne Austin biography

Roxanne S. Austin is an Independent Director of the Company. Ms. Austin is president of Austin Investment Advisors, a private investment and consulting firm, and chairs the U.S. Mid-market Investment Advisory Committee of EQT Partners. Previously, Ms. Austin also served as the president and chief executive officer of Move Networks, Inc., a provider of Internet television services. Ms. Austin served as president and chief operating officer of DIRECTV, Inc. Ms. Austin also served as executive vice president and chief financial officer of Hughes Electronics Corporation and as a partner of Deloitte & Touche LLP. Ms. Austin is also a director of Abbott Laboratories, Target Corporation, and Teledyne Technologies, Inc. Ms. Austin also served as a director of Telefonaktiebolaget LM Ericsson from 2008 to 2016. Through her extensive management and operating roles, including her financial roles, Ms. Austin contributes significant oversight and leadership experience to the board, including financial expertise and knowledge of financial statements, corporate finance and accounting matters.

What is the salary of Roxanne Austin?

As the Independent Director of Abbvie Inc, the total compensation of Roxanne Austin at Abbvie Inc is $333,427. There are 16 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.

How old is Roxanne Austin?

Roxanne Austin is 59, she's been the Independent Director of Abbvie Inc since 2013. There are 11 older and 20 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.

What's Roxanne Austin's mailing address?

Roxanne's mailing address filed with the SEC is C/O CROWDSTRIKE HOLDINGS, INC., 206 E. 9TH ST., STE. 1400, AUSTIN, TX, 78701.

Insiders trading at Abbvie Inc

Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell und Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.

What does Abbvie Inc do?

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Complete history of Ms. Austin stock trades at Abbott Laboratories, Abbvie Inc, Target Corp, Teledyne Technologies Inc, Verizon Communications Inc und Crowdstrike Inc

Abbvie Inc executives and stock owners

Abbvie Inc executives and other stock owners filed with the SEC include:

• Richard Gonzalez,
  Chairman of the Board, Chief Executive Officer
• Laura Schumacher,
  Vice Chairman, External Affairs and Chief Legal Officer
• Carlos Alban,
  Vice Chairman, Chief Commercial Officer
• Michael Severino,
  President, Vice Chairman
• Robert Michael,
  Chief Financial Officer, Senior Vice President
• William Chase,
  Executive Vice President - Finance and Administration
• Richard A. Gonzalez,
  Chairman & CEO
• Dr. Michael E. Severino,
  Vice Chairman & Pres
• Laura J. Schumacher,
  Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
• Timothy Richmond,
  Chief Human Resource Officer, Executive Vice President
• Robert A. Michael,
  Vice Chairman of Fin. & Commercial Operations and CFO
• Glenn Tilton,
  Lead Independent Director
• Robert Alpern,
  Independent Director
• Edward Rapp,
  Independent Director
• Brett Hart,
  Independent Director
• William Burnside,
  Independent Director
• Roxanne Austin,
  Independent Director
• Frederick Waddell,
  Independent Director
• Melody Meyer,
  Independent Director
• Edward Liddy,
  Independent Director
• Thomas Freyman,
  Independent Director
• Rebecca Roberts,
  Independent Director
• Brian Durkin,
  Vice President, Controller
• Jeffrey Stewart,
  Senior Vice President, U.S. Commercial Operations
• Nicholas Donoghoe,
  Senior Vice President - Enterprise Innovation
• Azita Saleki-Gerhardt,
  Executive Vice President - Operations
• Henry Gosebruch,
  Executive Vice President, Chief Strategy Officer
• Scott T. Reents,
  Sr. VP & CFO
• Jeffrey Ryan Stewart,
  Exec. VP & Chief Commercial Officer
• Henry O. Gosebruch,
  Exec. VP & Chief Strategy Officer
• Scott C. Brun M.D.,
  VP of Scientific Affairs & Head of AbbVie Ventures
• Timothy J. Richmond,
  Exec. VP & Chief HR Officer
• Elizabeth Shea,
  VP of Investor Relations
• Dr. Thomas J. Hudson,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Azita Saleki-Gerhardt,
  Exec. VP of Operations
• Thomas A. Hurwich,
  VP, Controller
• Jennifer L. Davis,
  
• Roy S Roberts,
  Director
• Laboratories Abbott,
  10% owner
• John M Leonard,
  SVP, Chief Scientific Officer
• Elaine K. Sorg,
  SVP, US COMMERCIAL OPERATIONS
• Perry C Siatis,
  EVP, GC AND SECRETARY
• Carrie C Strom,
  SVP & PRES GLOBAL ALLERG AESTH
• Thomas J Hudson,
  SVP, CSO, GLOBAL RESEARCH
• Scott T Reents,
  EVP, CHIEF FINANCIAL OFFICER
• Susan E Quaggin,
  
• Kevin K Buckbee,
  SVP, CONTROLLER
• Roopal Thakkar,
  SVP, CMO, GLOBAL THERAPEUTICS